US EditionKelso Pharma secures £140m of acquisition funding and appoints senior pharma executive as Non-Executive Director - Scottish Business News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Kelso Pharma secures £140m of acquisition funding and appoints senior pharma executive as Non-Executive Director - Scottish Business News
Kelso Pharma, the growing specialty pharma business backed by Apposite Capital, the healthcare specialist private equity investor, announces that it has secured over £140 million of acquisition funding and appointed former ADVANZ PHARMA CEO, Graeme Duncan, as Non-Executive Director. A proportion of the funding was used by Kelso Pharma in its acquisition of ALTURiX last month. The remaining facilities will be used to facilitate further acquisitio…
Kelso Pharma secures £140m of acquisition funding and appoints senior pharma executive as Non-Executive Director - Spreng Thomson
Kelso Pharma, the growing specialty pharma business backed by Apposite Capital, the healthcare specialist private equity investor, announces that it has secured over £140 million of acquisition funding and appointed former ADVANZ PHARMA CEO, Graeme Duncan, as Non-Executive Director. The post Kelso Pharma secures £140m of acquisition funding and appoints senior pharma executive as Non-Executive Director appeared first on Spreng Thomson.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
